A compliance expert outlines what's next for GLP-1 compounding oversight and how pharmacists can stay audit-ready.
Annie Lambert, PharmD, BCSCP
Advertisement
Annie Lambert, PharmD, BCSCP is Clinical Program Manager for Compliance Solutions at Wolters Kluwer.
Articles by Annie Lambert, PharmD, BCSCP
A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.
Pharmacy leaders navigate complex compliance challenges, budget constraints, and evolving technology to enhance safety and efficiency in compounding practices.
As pharmacists were pulled into patient-facing roles, many hospitals were forced to scale back or make adjustments in medication compounding practices.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
World Lung Cancer Day: Pharmacists Are Essential Across Prevention, Screening, and Treatment
2
A Pharmacist's Guide to Probiotics for Preventing Traveler’s Diarrhea
3
July 2026 in Pain Management: 10 Developments That Advanced and Challenged Patient Care
4
Five Solid Tumor Advances That Defined July 2026
5